Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology.
Exenatide, a GLP-1 analog, is currently only marketed in injectable form, and is indicated for the treatment of Type 2 diabetes. Exenatide has an excellent safety profile and a plethora of positive medicinal effects including weight loss and improved pancreatic cell function.
http://www.digitaljournal.com/pr/1633129
aka Byetta...
Exenatide, a GLP-1 analog, is currently only marketed in injectable form, and is indicated for the treatment of Type 2 diabetes. Exenatide has an excellent safety profile and a plethora of positive medicinal effects including weight loss and improved pancreatic cell function.
http://www.digitaljournal.com/pr/1633129
aka Byetta...